Timeline

Gabriel Aymé

Research Engineer

18 Mar 2024

publication

Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanisms

25 Sep 2023

publication

An original potentiating mechanism revealed by the cryo-EM structures of the human α7 nicotinic receptor in complex with nanobodies.

22 Jun 2023

event

Single-Domain Antibodies 2023

25 May 2023

publication

Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor.

09 Mar 2023

publication

Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.

25 Oct 2022

project

Advances in cancer immunotherapy development: VHH-based immune checkpoint inhibitors targeting the receptor ILT4

01 Jan 2022

publication

Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein.

10 Apr 2020

project

CORONABODIES

07 Apr 2020

publication

Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.

16 Jan 2020

project

VenoMATIcs: Toward a Global Management of Venoms and Envenomations: the Pasteur network Translational Approach

13 Sep 2018

publication

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

01 Apr 2018

publication

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

27 Feb 2018

project

Toxins and VHHs as subtype-specific ligands and allosteric modulators of nicotinic acetylcholine receptors (PTR Nicobinder)

01 Sep 2017

publication

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

27 Apr 2017

publication

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

06 Oct 2016

publication

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

17 Feb 2015

team

A little guide for advanced search:

Timeline

Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanisms

An original potentiating mechanism revealed by the cryo-EM structures of the human α7 nicotinic receptor in complex with nanobodies.

Single-Domain Antibodies 2023

Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor.

Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.

Advances in cancer immunotherapy development: VHH-based immune checkpoint inhibitors targeting the receptor ILT4

Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein.

CORONABODIES

Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.

VenoMATIcs: Toward a Global Management of Venoms and Envenomations: the Pasteur network Translational Approach

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

Toxins and VHHs as subtype-specific ligands and allosteric modulators of nicotinic acetylcholine receptors (PTR Nicobinder)

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Antibody Engineering